Curative Biotechnology, Inc.
CUBT
$0.01
$0.005.46%
OTC PK
| 03/31/2025 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -64.51% | -83.63% | 22.84% | -91.75% | 9,489.61% |
| Depreciation & Amortization | -17.05% | 0.00% | 150.00% | 53.85% | 53.85% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -62.91% | -62.77% | 111.46% | -79.39% | 9,525.56% |
| Operating Income | 62.91% | 62.77% | -111.46% | 79.39% | -9,525.56% |
| Income Before Tax | 56.48% | 50.40% | -76.07% | 79.63% | -10,057.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 56.48% | 50.40% | -76.07% | 79.63% | -10,057.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.48% | 50.40% | -76.07% | 79.63% | -10,057.00% |
| EBIT | 62.91% | 62.77% | -111.46% | 79.39% | -9,525.56% |
| EBITDA | 64.55% | 62.82% | -111.37% | 79.39% | -11,124.68% |
| EPS Basic | 8.33% | 61.67% | 92.75% | -84.06% | -- |
| Normalized Basic EPS | 62.50% | 54.84% | -15.38% | 88.37% | -- |
| EPS Diluted | 8.33% | 61.67% | 92.75% | -84.06% | -- |
| Normalized Diluted EPS | 62.50% | 54.84% | -15.38% | 88.37% | -- |
| Average Basic Shares Outstanding | 3.19% | 8.01% | 52.36% | 70.22% | 66.20% |
| Average Diluted Shares Outstanding | 3.19% | 8.01% | 52.36% | 70.22% | 66.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |